The INCH trial - Induction chemotherapy in patients with bulky anal canal cancer: Evaluation of the pilot phase

Francesca De Felice, Alessia Fallarino, Franco Iafrate, Veronica Maiuri, Giovanni Galloni, Giovanni Turriziani Colonna, Raffaella De Pietro, Giuseppina Chiarello, Claudia Marchetti, Nadia Bulzonetti, Daniela Musio, Vincenzo Tombolini

Risultato della ricerca: Contributo in rivistaArticolo in rivista


Aim: To assess feasibility, complications and efficacy of induction chemotherapy followed by standard chemoradiotherapy in patients with bulky anal canal cancer. Patients and Methods: Patients with squamous cell carcinoma of the anal canal, staged bulky tumor with or without nodal involvement were prospectively enrolled. Before standard chemoradiotherapy, patients received induction chemotherapy with 3 cycles of 75 mg/m2cisplatin and 750 mg/m25-fluorouracil. Patients were followed-up routinely until recurrence or death. Results: Seven patients with bulky anal canal cancer were evaluable for this pilot phase of the study. All patients had human papillomavirusnegative disease. Five completed the scheduled induction chemotherapy and all patients completed the programmed concomitant chemoradiotherapy. None had severe hematological toxicity. The majority of patients (6/7) had tumor downsizing after induction treatment. Six months after chemoradiotherapy, complete response was documented in three patients and salvage surgery was performed in two cases. With a median follow-up of 38 months (range=28-48 months), two patients are disease-free survivors. Conclusion: Induction chemotherapy has the potential to become a standard approach in patients with bulky human papillomavirus-negative anal canal cancer.
Lingua originaleEnglish
pagine (da-a)3187-3191
Numero di pagine5
RivistaAnticancer Research
Stato di pubblicazionePubblicato - 2021


  • 5-FU
  • Anal canal carcinoma
  • Chemoradiotherapy
  • Cisplatin
  • Induction chemotherapy
  • Prospective study


Entra nei temi di ricerca di 'The INCH trial - Induction chemotherapy in patients with bulky anal canal cancer: Evaluation of the pilot phase'. Insieme formano una fingerprint unica.

Cita questo